Jan Kaiserle

A groundbreaking study published in the journal Genes has fundamentally altered the scientific landscape for hypermobile Ehlers-Danlos syndrome (hEDS), proposing that the condition’s origins are not rooted in a single genetic flaw but rather a complex accumulation of variants across three distinct

The paradigm of healthcare delivery is undergoing a fundamental and rapid transformation, moving away from traditional in-person visits toward a more accessible, data-driven, and remote model. This evolution is not merely a consequence of recent global events but the culmination of technological

The single greatest risk factor for developing Parkinson's disease has been systematically overlooked in the very laboratories dedicated to finding a cure, a baffling disconnect that a global consortium of scientists is now moving urgently to correct. For decades, the relentless march toward

The burgeoning market for GLP-1 weight-loss medications created a gold rush for telehealth companies, but for Hims & Hers, a bold move into this lucrative space has rapidly devolved into a multi-front battle with regulators and pharmaceutical giants. The company's recent announcement that it would

A groundbreaking study offers a novel strategy in the relentless fight against neurodegeneration by borrowing one of modern oncology's most powerful weapons and turning it against the pathologies of the brain. The research demonstrates, for the first time in a living animal model, that an

A single rogue protein, present in nearly every person diagnosed with amyotrophic lateral sclerosis, has long been the focus of intense scientific pursuit and a major roadblock to effective treatment. Netherlands-based biotechnology company VectorY Therapeutics has now initiated a landmark clinical

An experimental oral medication for obesity has delivered substantial weight loss in a mid-stage trial, heralding the arrival of a formidable new challenger in a market dominated by pharmaceutical titans. Co-developed by Hengrui Pharma and Kailera Therapeutics, the pill, known as ribupatide,

The long-held view of enzymes as nature's exquisitely specific but single-minded catalysts is undergoing a profound transformation, giving way to a new paradigm that reimagines them as versatile, programmable molecular machines. This significant shift, fueled by remarkable discoveries in natural

The landscape of laboratory research is undergoing a profound transformation, moving away from siloed operations and toward a future defined by intelligent, interconnected automation. At the upcoming SLAS 2026 conference in Boston, ABB Robotics is set to demonstrate a significant leap forward in

The ambitious journey of bringing a groundbreaking therapy from a laboratory concept to a patient-ready treatment is increasingly intersecting with the harsh realities of a complex and fragmented manufacturing landscape. As biopharmaceutical innovators pioneer increasingly sophisticated molecules,